<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540228</url>
  </required_header>
  <id_info>
    <org_study_id>110794</org_study_id>
    <nct_id>NCT00540228</nct_id>
  </id_info>
  <brief_title>Study to Evaluate an Influenza Vaccine Candidate</brief_title>
  <official_title>Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza Vaccine GSK1247446A With Various Formulations in Subjects Aged 18-64 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      In order to find the formulation leading to a maximal increase of the immune response while
      maintaining an acceptable safety profile, this study is designed to evaluate the
      immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals'
      influenza vaccine administered in adults aged 18-64 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 5, 2007</start_date>
  <completion_date type="Actual">May 8, 2008</completion_date>
  <primary_completion_date type="Actual">May 8, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Days 0, 21 and 180</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA). The seropositivity cut-off assay was 1:10. The results for Day 0 and Day 21 are the primary efficacy variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Days 21 and 180</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Days 21 and 180</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.</measure>
    <time_frame>At Days 0, 21 and 180</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The 4 influenza strains assessed were A/Wisconsin (WISC), B/Malaysia (MALA), A/Brisbane (BRIS) and B/Florida (FLOR). The seropositivity cut-off assay was 1:28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 4 T-cells.</measure>
    <time_frame>At Days 0, 21 and 180</time_frame>
    <description>The mean was calculated for CD4 T-cells (per million CD4 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-γ), at least IL2 and at least TNF alpha (TNF-α).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 8 T-cells.</measure>
    <time_frame>At Days 0, 21 and 180</time_frame>
    <description>The mean was calculated for CD8 T-cells (per million CD8 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-γ), at least IL2 and at least TNF alpha (TNF-α).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post vaccination period</time_frame>
    <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal everyday activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post vaccination period</time_frame>
    <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [oral temperature above (&gt;) 38.0 degrees Celsius (°C)], headache, myalgia, nausea and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Medically Significant Conditions (MSCs).</measure>
    <time_frame>From Day 0 to Day 180</time_frame>
    <description>MSCs were defined as conditions prompting emergency room visits or physician visits that were not related to common diseases or routine visits. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 = event which prevented normal activities. Related = event assessed by the investigator as causally related to the study vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</measure>
    <time_frame>During the 21-day (Days 0-20) post vaccination period</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs).</measure>
    <time_frame>From Day 0 to Day 180</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1006</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK1247446A 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1247446A 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1247446A 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1247446A 4 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccine GSK1247446A - 4 different formulations</intervention_name>
    <description>Single dose, Intramuscular injection</description>
    <arm_group_label>GSK1247446A 2 Group</arm_group_label>
    <arm_group_label>GSK1247446A 1 Group</arm_group_label>
    <arm_group_label>GSK1247446A 4 Group</arm_group_label>
    <arm_group_label>GSK1247446A 3 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™</intervention_name>
    <description>Single dose, Intramuscular injection</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only subjects who the investigator believes that they can and will comply with the
             requirements of the protocol .

          -  A male or female between, and including, 18 - 64 years of age at the time of
             vaccination.

          -  Written informed consent obtained from the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  If the subject is female, she must be of non-childbearing potential or if she is of
             childbearing potential, she must have a negative pregnancy test, practice adequate
             contraception for 30 days prior to vaccination, and continue such precautions for 2
             months after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within three months prior to the first vaccine dose

          -  Administration of a vaccine not foreseen by the study protocol from 30 days before
             vaccination, up to 21 days after vaccination.

          -  History of hypersensitivity to a previous dose of influenza vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s)

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory screening
             tests.

          -  Confirmed influenza infection within a year preceding the study start.

          -  Administration of an influenza vaccine within a year preceding the study start.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Pregnant or lactating female.

          -  Concurrent participation in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product

          -  Acute disease at the time of enrolment.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.

          -  Any condition which, in the opinion of the investigator, prevents the subject from
             participating in the study.

          -  History of administration of experimental/licensed vaccine containing squalene and/or
             tocopherol within the last 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caen cedex 4</city>
        <zip>14052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lagord</city>
        <zip>17140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiberg</city>
        <state>Sachsen</state>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schmiedeberg</city>
        <state>Sachsen</state>
        <zip>01762</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2007</study_first_posted>
  <results_first_submitted>March 14, 2013</results_first_submitted>
  <results_first_submitted_qc>March 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2013</results_first_posted>
  <disposition_first_submitted>May 8, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 25, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2009</disposition_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Influenza Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110794</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110794</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110794</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110794</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110794</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110794</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GSK1247446A 1 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>GSK1247446A 2 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>GSK1247446A 3 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>GSK1247446A 4 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P5">
          <title>Fluarix Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="204"/>
                <participants group_id="P4" count="202"/>
                <participants group_id="P5" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="197"/>
                <participants group_id="P3" count="204"/>
                <participants group_id="P4" count="202"/>
                <participants group_id="P5" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK1247446A 1 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>GSK1247446A 2 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>GSK1247446A 3 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>GSK1247446A 4 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Fluarix Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="204"/>
            <count group_id="B4" value="202"/>
            <count group_id="B5" value="202"/>
            <count group_id="B6" value="1006"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="14.14"/>
                    <measurement group_id="B2" value="40.3" spread="13.79"/>
                    <measurement group_id="B3" value="39.7" spread="14.37"/>
                    <measurement group_id="B4" value="39.7" spread="14.31"/>
                    <measurement group_id="B5" value="40.1" spread="14.11"/>
                    <measurement group_id="B6" value="40.1" spread="14.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="140"/>
                    <measurement group_id="B5" value="123"/>
                    <measurement group_id="B6" value="609"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="79"/>
                    <measurement group_id="B6" value="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
        <description>Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA). The seropositivity cut-off assay was 1:10. The results for Day 0 and Day 21 are the primary efficacy variables.</description>
        <time_frame>At Days 0, 21 and 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
          <description>Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA). The seropositivity cut-off assay was 1:10. The results for Day 0 and Day 21 are the primary efficacy variables.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="192"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SOLO, Day 0 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="10.9" upper_limit="15.5"/>
                    <measurement group_id="O2" value="12.3" lower_limit="10.2" upper_limit="14.8"/>
                    <measurement group_id="O3" value="12.9" lower_limit="10.6" upper_limit="15.8"/>
                    <measurement group_id="O4" value="14.9" lower_limit="12.3" upper_limit="18.2"/>
                    <measurement group_id="O5" value="15.1" lower_limit="12.5" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOLO, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.2" lower_limit="171.7" upper_limit="240.3"/>
                    <measurement group_id="O2" value="155.8" lower_limit="128.2" upper_limit="189.4"/>
                    <measurement group_id="O3" value="164.9" lower_limit="137.6" upper_limit="197.8"/>
                    <measurement group_id="O4" value="151.1" lower_limit="124.7" upper_limit="183.1"/>
                    <measurement group_id="O5" value="191.0" lower_limit="158.5" upper_limit="230.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOLO, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" lower_limit="68.3" upper_limit="96.8"/>
                    <measurement group_id="O2" value="71.1" lower_limit="58.8" upper_limit="86.1"/>
                    <measurement group_id="O3" value="76.3" lower_limit="63.2" upper_limit="92.0"/>
                    <measurement group_id="O4" value="80.7" lower_limit="66.7" upper_limit="97.5"/>
                    <measurement group_id="O5" value="97.6" lower_limit="82.5" upper_limit="115.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 0 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" lower_limit="23.8" upper_limit="36.4"/>
                    <measurement group_id="O2" value="30.0" lower_limit="24.3" upper_limit="37.2"/>
                    <measurement group_id="O3" value="29.9" lower_limit="24.5" upper_limit="36.5"/>
                    <measurement group_id="O4" value="27.2" lower_limit="22.6" upper_limit="32.8"/>
                    <measurement group_id="O5" value="37.4" lower_limit="30.2" upper_limit="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.1" lower_limit="321.3" upper_limit="449.8"/>
                    <measurement group_id="O2" value="326.4" lower_limit="275.6" upper_limit="386.7"/>
                    <measurement group_id="O3" value="319.9" lower_limit="270.0" upper_limit="379.1"/>
                    <measurement group_id="O4" value="273.9" lower_limit="232.0" upper_limit="323.3"/>
                    <measurement group_id="O5" value="335.3" lower_limit="286.2" upper_limit="392.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.3" lower_limit="145.6" upper_limit="208.8"/>
                    <measurement group_id="O2" value="149.5" lower_limit="125.3" upper_limit="178.3"/>
                    <measurement group_id="O3" value="164.0" lower_limit="138.0" upper_limit="195.0"/>
                    <measurement group_id="O4" value="133.0" lower_limit="112.5" upper_limit="157.3"/>
                    <measurement group_id="O5" value="176.2" lower_limit="151.7" upper_limit="204.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 0 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" lower_limit="21.3" upper_limit="31.3"/>
                    <measurement group_id="O2" value="27.3" lower_limit="22.6" upper_limit="32.9"/>
                    <measurement group_id="O3" value="22.6" lower_limit="18.8" upper_limit="27.1"/>
                    <measurement group_id="O4" value="23.2" lower_limit="19.5" upper_limit="27.8"/>
                    <measurement group_id="O5" value="27.0" lower_limit="22.2" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.8" lower_limit="195.3" upper_limit="261.1"/>
                    <measurement group_id="O2" value="246.1" lower_limit="210.9" upper_limit="287.2"/>
                    <measurement group_id="O3" value="195.5" lower_limit="165.1" upper_limit="231.4"/>
                    <measurement group_id="O4" value="171.2" lower_limit="144.2" upper_limit="203.2"/>
                    <measurement group_id="O5" value="217.8" lower_limit="184.3" upper_limit="257.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.6" lower_limit="91.7" upper_limit="124.0"/>
                    <measurement group_id="O2" value="119.6" lower_limit="103.7" upper_limit="138.0"/>
                    <measurement group_id="O3" value="97.2" lower_limit="83.2" upper_limit="113.5"/>
                    <measurement group_id="O4" value="95.7" lower_limit="82.1" upper_limit="111.7"/>
                    <measurement group_id="O5" value="108.8" lower_limit="93.1" upper_limit="127.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA).</description>
        <time_frame>At Days 21 and 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="192"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SOLO, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="133"/>
                    <measurement group_id="O4" value="119"/>
                    <measurement group_id="O5" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOLO, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="102"/>
                    <measurement group_id="O5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="142"/>
                    <measurement group_id="O4" value="142"/>
                    <measurement group_id="O5" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="106"/>
                    <measurement group_id="O5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="127"/>
                    <measurement group_id="O5" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="102"/>
                    <measurement group_id="O5" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA).</description>
        <time_frame>At Days 21 and 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease.</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="192"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SOLO, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="12.7" upper_limit="19.2"/>
                    <measurement group_id="O2" value="12.7" lower_limit="10.2" upper_limit="15.8"/>
                    <measurement group_id="O3" value="12.8" lower_limit="10.1" upper_limit="16.1"/>
                    <measurement group_id="O4" value="10.1" lower_limit="8.0" upper_limit="12.8"/>
                    <measurement group_id="O5" value="12.7" lower_limit="9.9" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOLO, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="5.3" upper_limit="7.7"/>
                    <measurement group_id="O2" value="5.9" lower_limit="4.8" upper_limit="7.2"/>
                    <measurement group_id="O3" value="5.9" lower_limit="4.8" upper_limit="7.2"/>
                    <measurement group_id="O4" value="5.4" lower_limit="4.4" upper_limit="6.7"/>
                    <measurement group_id="O5" value="6.5" lower_limit="5.2" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="10.5" upper_limit="16.0"/>
                    <measurement group_id="O2" value="10.9" lower_limit="8.9" upper_limit="13.3"/>
                    <measurement group_id="O3" value="10.7" lower_limit="8.6" upper_limit="13.2"/>
                    <measurement group_id="O4" value="10.1" lower_limit="10.1" upper_limit="12.3"/>
                    <measurement group_id="O5" value="9.0" lower_limit="7.2" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="5.0" upper_limit="7.2"/>
                    <measurement group_id="O2" value="5.0" lower_limit="4.2" upper_limit="6.1"/>
                    <measurement group_id="O3" value="5.4" lower_limit="4.5" upper_limit="6.6"/>
                    <measurement group_id="O4" value="4.9" lower_limit="4.1" upper_limit="5.9"/>
                    <measurement group_id="O5" value="4.7" lower_limit="3.9" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="7.2" upper_limit="10.6"/>
                    <measurement group_id="O2" value="9.0" lower_limit="7.3" upper_limit="11.2"/>
                    <measurement group_id="O3" value="8.7" lower_limit="7.0" upper_limit="10.8"/>
                    <measurement group_id="O4" value="7.4" lower_limit="6.1" upper_limit="8.9"/>
                    <measurement group_id="O5" value="8.1" lower_limit="6.6" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.5" upper_limit="4.9"/>
                    <measurement group_id="O2" value="4.4" lower_limit="3.6" upper_limit="5.3"/>
                    <measurement group_id="O3" value="4.4" lower_limit="3.6" upper_limit="5.3"/>
                    <measurement group_id="O4" value="4.1" lower_limit="3.5" upper_limit="4.8"/>
                    <measurement group_id="O5" value="4.0" lower_limit="3.3" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.</title>
        <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA).</description>
        <time_frame>At Days 0, 21 and 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.</title>
          <description>A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 3 influenza strains assessed were A/Solomon Islands (SOLO), A/Wisconsin (WISC) and B/Malaysia (MALA).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="192"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SOLO, Day 0 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOLO, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="169"/>
                    <measurement group_id="O4" value="166"/>
                    <measurement group_id="O5" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOLO, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="151"/>
                    <measurement group_id="O5" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 0 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="91"/>
                    <measurement group_id="O5" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="185"/>
                    <measurement group_id="O4" value="184"/>
                    <measurement group_id="O5" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="175"/>
                    <measurement group_id="O4" value="173"/>
                    <measurement group_id="O5" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 0 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 21 [N=187;189;190;192;185]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="180"/>
                    <measurement group_id="O4" value="180"/>
                    <measurement group_id="O5" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 180 [N=189;190;192;192;187]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="167"/>
                    <measurement group_id="O4" value="171"/>
                    <measurement group_id="O5" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.</title>
        <description>Titers are presented as geometric mean titers (GMTs). The 4 influenza strains assessed were A/Wisconsin (WISC), B/Malaysia (MALA), A/Brisbane (BRIS) and B/Florida (FLOR). The seropositivity cut-off assay was 1:28.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.</title>
          <description>Titers are presented as geometric mean titers (GMTs). The 4 influenza strains assessed were A/Wisconsin (WISC), B/Malaysia (MALA), A/Brisbane (BRIS) and B/Florida (FLOR). The seropositivity cut-off assay was 1:28.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WISC, Day 0 [N=43;47;44;43;42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.3" lower_limit="94.6" upper_limit="190.8"/>
                    <measurement group_id="O2" value="136.3" lower_limit="101.4" upper_limit="183.1"/>
                    <measurement group_id="O3" value="160.8" lower_limit="111.0" upper_limit="232.9"/>
                    <measurement group_id="O4" value="148.0" lower_limit="107.0" upper_limit="204.5"/>
                    <measurement group_id="O5" value="212.5" lower_limit="138.2" upper_limit="326.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WISC, Day 21 [N=47;48;44;47;42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1193.7" lower_limit="876.6" upper_limit="1625.5"/>
                    <measurement group_id="O2" value="859.6" lower_limit="637.8" upper_limit="1158.5"/>
                    <measurement group_id="O3" value="1027.9" lower_limit="760.3" upper_limit="1389.8"/>
                    <measurement group_id="O4" value="842.3" lower_limit="641.9" upper_limit="1105.2"/>
                    <measurement group_id="O5" value="864.0" lower_limit="654.2" upper_limit="1140.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 0 [N=46;48;44;44;42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="25.7" upper_limit="45.1"/>
                    <measurement group_id="O2" value="36.5" lower_limit="25.9" upper_limit="51.3"/>
                    <measurement group_id="O3" value="33.3" lower_limit="24.4" upper_limit="45.4"/>
                    <measurement group_id="O4" value="27.7" lower_limit="21.1" upper_limit="36.2"/>
                    <measurement group_id="O5" value="49.7" lower_limit="35.2" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALA, Day 21 [N=44;48;43;42;42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.5" lower_limit="117.6" upper_limit="224.5"/>
                    <measurement group_id="O2" value="161.5" lower_limit="128.6" upper_limit="202.9"/>
                    <measurement group_id="O3" value="141.0" lower_limit="103.8" upper_limit="191.3"/>
                    <measurement group_id="O4" value="130.5" lower_limit="98.7" upper_limit="172.7"/>
                    <measurement group_id="O5" value="166.0" lower_limit="111.2" upper_limit="247.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRIS, Day 0 [N=47;48;44;47;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494.2" lower_limit="389.0" upper_limit="627.7"/>
                    <measurement group_id="O2" value="365.9" lower_limit="298.3" upper_limit="449.0"/>
                    <measurement group_id="O3" value="392.5" lower_limit="319.1" upper_limit="482.8"/>
                    <measurement group_id="O4" value="445.7" lower_limit="369.2" upper_limit="538.0"/>
                    <measurement group_id="O5" value="466.8" lower_limit="355.2" upper_limit="613.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRIS, Day 21 [N=47;48;44;47;42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1151.5" lower_limit="901.8" upper_limit="1470.4"/>
                    <measurement group_id="O2" value="847.5" lower_limit="668.0" upper_limit="1075.3"/>
                    <measurement group_id="O3" value="884.2" lower_limit="673.2" upper_limit="1161.2"/>
                    <measurement group_id="O4" value="1038.2" lower_limit="799.3" upper_limit="1348.6"/>
                    <measurement group_id="O5" value="867.1" lower_limit="658.9" upper_limit="1141.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLOR, Day 0 [N=45;48;44;47;42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" lower_limit="35.2" upper_limit="67.9"/>
                    <measurement group_id="O2" value="56.9" lower_limit="38.6" upper_limit="83.9"/>
                    <measurement group_id="O3" value="51.0" lower_limit="35.2" upper_limit="73.9"/>
                    <measurement group_id="O4" value="46.8" lower_limit="32.7" upper_limit="66.9"/>
                    <measurement group_id="O5" value="76.7" lower_limit="51.1" upper_limit="115.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLOR, Day 21 [N=43;48;43;43;42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" lower_limit="68.8" upper_limit="129.3"/>
                    <measurement group_id="O2" value="113.6" lower_limit="79.7" upper_limit="162.0"/>
                    <measurement group_id="O3" value="92.1" lower_limit="60.6" upper_limit="139.9"/>
                    <measurement group_id="O4" value="82.7" lower_limit="57.9" upper_limit="118.2"/>
                    <measurement group_id="O5" value="131.1" lower_limit="93.3" upper_limit="184.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 4 T-cells.</title>
        <description>The mean was calculated for CD4 T-cells (per million CD4 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-γ), at least IL2 and at least TNF alpha (TNF-α).</description>
        <time_frame>At Days 0, 21 and 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 4 T-cells.</title>
          <description>The mean was calculated for CD4 T-cells (per million CD4 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-γ), at least IL2 and at least TNF alpha (TNF-α).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Doubles, Day 0 [N=45;47;43;47;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2106.16" spread="1274.90"/>
                    <measurement group_id="O2" value="2043.17" spread="894.18"/>
                    <measurement group_id="O3" value="2252.44" spread="1726.88"/>
                    <measurement group_id="O4" value="2103.66" spread="1370.89"/>
                    <measurement group_id="O5" value="1976.23" spread="1051.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles, Day 21 [N=45;45;40;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3857.76" spread="2195.47"/>
                    <measurement group_id="O2" value="3366.93" spread="1693.40"/>
                    <measurement group_id="O3" value="3103.30" spread="1549.21"/>
                    <measurement group_id="O4" value="2827.84" spread="1561.60"/>
                    <measurement group_id="O5" value="2489.15" spread="1468.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles, Day 180 [N=46;42;42;43;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2628.96" spread="1353.46"/>
                    <measurement group_id="O2" value="2249.88" spread="1325.73"/>
                    <measurement group_id="O3" value="1963.38" spread="1245.21"/>
                    <measurement group_id="O4" value="2153.12" spread="1473.45"/>
                    <measurement group_id="O5" value="1952.02" spread="1240.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, Day 0 [N=45;47;43;47;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1914.96" spread="1241.38"/>
                    <measurement group_id="O2" value="1863.96" spread="830.55"/>
                    <measurement group_id="O3" value="2045.86" spread="1638.11"/>
                    <measurement group_id="O4" value="1954.13" spread="1290.77"/>
                    <measurement group_id="O5" value="1827.67" spread="1033.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, Day 21 [N=45;45;40;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3337.89" spread="1982.59"/>
                    <measurement group_id="O2" value="2947.20" spread="1487.13"/>
                    <measurement group_id="O3" value="2624.30" spread="1316.60"/>
                    <measurement group_id="O4" value="2472.98" spread="1378.17"/>
                    <measurement group_id="O5" value="2223.74" spread="1398.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, Day 180 [N=46;42;42;43;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2108.04" spread="1190.42"/>
                    <measurement group_id="O2" value="1758.95" spread="1093.80"/>
                    <measurement group_id="O3" value="1581.31" spread="1184.99"/>
                    <measurement group_id="O4" value="1731.00" spread="1331.05"/>
                    <measurement group_id="O5" value="1560.76" spread="1009.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ, Day 0 [N=45;47;43;47;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1379.33" spread="987.07"/>
                    <measurement group_id="O2" value="1377.13" spread="741.31"/>
                    <measurement group_id="O3" value="1510.84" spread="1349.58"/>
                    <measurement group_id="O4" value="1342.57" spread="1040.63"/>
                    <measurement group_id="O5" value="1260.97" spread="809.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ, Day 21 [N=45;45;40;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2525.91" spread="1615.78"/>
                    <measurement group_id="O2" value="2233.24" spread="1371.05"/>
                    <measurement group_id="O3" value="2056.40" spread="1205.90"/>
                    <measurement group_id="O4" value="1824.69" spread="1265.29"/>
                    <measurement group_id="O5" value="1565.79" spread="1064.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ, Day 180 [N=46;42;42;43;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1792.74" spread="1075.76"/>
                    <measurement group_id="O2" value="1546.55" spread="1055.94"/>
                    <measurement group_id="O3" value="1335.62" spread="970.49"/>
                    <measurement group_id="O4" value="1440.09" spread="1199.84"/>
                    <measurement group_id="O5" value="1299.95" spread="894.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, Day 0 [N=45;47;43;47;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1684.24" spread="983.48"/>
                    <measurement group_id="O2" value="1657.28" spread="744.17"/>
                    <measurement group_id="O3" value="1796.33" spread="1354.89"/>
                    <measurement group_id="O4" value="1732.91" spread="1140.54"/>
                    <measurement group_id="O5" value="1572.69" spread="812.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, Day 21 [N=45;45;40;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3020.09" spread="1741.78"/>
                    <measurement group_id="O2" value="2634.64" spread="1415.24"/>
                    <measurement group_id="O3" value="2343.15" spread="1199.20"/>
                    <measurement group_id="O4" value="2256.02" spread="1251.58"/>
                    <measurement group_id="O5" value="1933.10" spread="1153.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, Day 180 [N=46;42;42;43;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2121.67" spread="1088.48"/>
                    <measurement group_id="O2" value="1816.26" spread="1116.55"/>
                    <measurement group_id="O3" value="1571.19" spread="987.96"/>
                    <measurement group_id="O4" value="1797.79" spread="1228.49"/>
                    <measurement group_id="O5" value="1581.73" spread="1028.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, Day 0 [N=45;47;43;47;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1606.64" spread="1087.17"/>
                    <measurement group_id="O2" value="1522.70" spread="747.67"/>
                    <measurement group_id="O3" value="1712.42" spread="1355.23"/>
                    <measurement group_id="O4" value="1548.00" spread="1094.03"/>
                    <measurement group_id="O5" value="1421.82" spread="781.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, Day 21 [N=45;45;40;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2767.02" spread="1598.41"/>
                    <measurement group_id="O2" value="2337.38" spread="1068.82"/>
                    <measurement group_id="O3" value="2109.45" spread="1075.51"/>
                    <measurement group_id="O4" value="1990.60" spread="1157.58"/>
                    <measurement group_id="O5" value="1639.31" spread="975.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, Day 180 [N=46;42;42;43;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1980.39" spread="1078.92"/>
                    <measurement group_id="O2" value="1654.90" spread="944.90"/>
                    <measurement group_id="O3" value="1454.40" spread="898.01"/>
                    <measurement group_id="O4" value="1627.67" spread="1155.63"/>
                    <measurement group_id="O5" value="1392.05" spread="933.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 8 T-cells.</title>
        <description>The mean was calculated for CD8 T-cells (per million CD8 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-γ), at least IL2 and at least TNF alpha (TNF-α).</description>
        <time_frame>At Days 0, 21 and 180</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Influenza-specific Cluster of Differentiation (CD) 8 T-cells.</title>
          <description>The mean was calculated for CD8 T-cells (per million CD8 T-cells) producing at least two different cytokines (All Doubles), at least CD40L, at least INF gamma (IFN-γ), at least IL2 and at least TNF alpha (TNF-α).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Doubles, Day 0 [N=44;46;43;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.02" spread="113.85"/>
                    <measurement group_id="O2" value="109.63" spread="405.09"/>
                    <measurement group_id="O3" value="17.33" spread="33.12"/>
                    <measurement group_id="O4" value="64.47" spread="181.32"/>
                    <measurement group_id="O5" value="48.38" spread="82.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles, Day 21 [N=44;43;40;42;38]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.18" spread="106.55"/>
                    <measurement group_id="O2" value="50.09" spread="101.55"/>
                    <measurement group_id="O3" value="38.53" spread="67.21"/>
                    <measurement group_id="O4" value="109.86" spread="282.04"/>
                    <measurement group_id="O5" value="55.11" spread="126.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles, Day 180 [N=44;40;42;41;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.32" spread="99.11"/>
                    <measurement group_id="O2" value="126.13" spread="323.68"/>
                    <measurement group_id="O3" value="36.31" spread="95.06"/>
                    <measurement group_id="O4" value="97.27" spread="258.53"/>
                    <measurement group_id="O5" value="30.98" spread="62.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, Day 0 [N=44;46;43;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="12.37"/>
                    <measurement group_id="O2" value="5.91" spread="15.92"/>
                    <measurement group_id="O3" value="2.63" spread="8.06"/>
                    <measurement group_id="O4" value="16.27" spread="56.56"/>
                    <measurement group_id="O5" value="7.05" spread="20.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, Day 21 [N=44;43;40;42;38]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82" spread="28.38"/>
                    <measurement group_id="O2" value="10.09" spread="21.58"/>
                    <measurement group_id="O3" value="6.45" spread="16.03"/>
                    <measurement group_id="O4" value="50.83" spread="193.00"/>
                    <measurement group_id="O5" value="37.55" spread="117.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L, Day 180 [N=44;40;42;41;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.45" spread="35.59"/>
                    <measurement group_id="O2" value="15.88" spread="61.59"/>
                    <measurement group_id="O3" value="2.86" spread="8.48"/>
                    <measurement group_id="O4" value="1.68" spread="4.37"/>
                    <measurement group_id="O5" value="2.27" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ, Day 0 [N=44;46;43;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.50" spread="53.27"/>
                    <measurement group_id="O2" value="96.91" spread="375.61"/>
                    <measurement group_id="O3" value="14.42" spread="32.92"/>
                    <measurement group_id="O4" value="44.80" spread="137.59"/>
                    <measurement group_id="O5" value="17.31" spread="38.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ, Day 21 [N=44;43;40;42;38]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.86" spread="61.18"/>
                    <measurement group_id="O2" value="48.07" spread="106.65"/>
                    <measurement group_id="O3" value="25.65" spread="49.98"/>
                    <measurement group_id="O4" value="64.98" spread="178.63"/>
                    <measurement group_id="O5" value="32.11" spread="104.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ, Day 180 [N=44;40;42;41;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.18" spread="50.84"/>
                    <measurement group_id="O2" value="110.75" spread="303.91"/>
                    <measurement group_id="O3" value="20.62" spread="47.56"/>
                    <measurement group_id="O4" value="79.85" spread="239.36"/>
                    <measurement group_id="O5" value="19.80" spread="37.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, Day 0 [N=44;46;43;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.59" spread="91.49"/>
                    <measurement group_id="O2" value="75.41" spread="309.22"/>
                    <measurement group_id="O3" value="8.81" spread="16.65"/>
                    <measurement group_id="O4" value="46.22" spread="130.46"/>
                    <measurement group_id="O5" value="43.59" spread="81.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, Day 21 [N=44;46;43;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.98" spread="85.05"/>
                    <measurement group_id="O2" value="21.51" spread="42.47"/>
                    <measurement group_id="O3" value="31.28" spread="59.89"/>
                    <measurement group_id="O4" value="87.86" spread="244.84"/>
                    <measurement group_id="O5" value="50.84" spread="116.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL2, Day 180 [N=44;40;42;41;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.36" spread="87.59"/>
                    <measurement group_id="O2" value="74.03" spread="183.59"/>
                    <measurement group_id="O3" value="24.50" spread="82.62"/>
                    <measurement group_id="O4" value="57.15" spread="136.73"/>
                    <measurement group_id="O5" value="28.73" spread="55.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, Day 0 [N=44;46;43;45;39]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.98" spread="109.79"/>
                    <measurement group_id="O2" value="102.72" spread="391.96"/>
                    <measurement group_id="O3" value="15.42" spread="28.60"/>
                    <measurement group_id="O4" value="54.73" spread="156.41"/>
                    <measurement group_id="O5" value="46.18" spread="91.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, Day 21 [N=44;43;40;42;38]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.93" spread="109.46"/>
                    <measurement group_id="O2" value="44.16" spread="99.17"/>
                    <measurement group_id="O3" value="31.55" spread="59.52"/>
                    <measurement group_id="O4" value="90.48" spread="239.47"/>
                    <measurement group_id="O5" value="37.82" spread="110.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α, Day 180 [N=44;40;42;41;41]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.70" spread="86.94"/>
                    <measurement group_id="O2" value="111.10" spread="299.67"/>
                    <measurement group_id="O3" value="33.60" spread="80.50"/>
                    <measurement group_id="O4" value="79.54" spread="208.13"/>
                    <measurement group_id="O5" value="25.63" spread="56.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal everyday activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site.</description>
        <time_frame>During the 7-day (Days 0-6) post vaccination period</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
          <description>Assessed solicited local symptoms were ecchymosis, pain, redness and swelling at injection site. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal everyday activity. Grade 3 redness/swelling/ecchymosis = redness/swelling/ecchymosis spreading beyond 50 millimeters (mm) of the injection site.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="167"/>
                    <measurement group_id="O4" value="151"/>
                    <measurement group_id="O5" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [oral temperature above (&gt;) 38.0 degrees Celsius (°C)], headache, myalgia, nausea and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) post vaccination period</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.</title>
          <description>Assessed solicited general symptoms were arthralgia, fatigue, fever [oral temperature above (&gt;) 38.0 degrees Celsius (°C)], headache, myalgia, nausea and shivering. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.0°C. Related = symptom considered by the investigator to have a causal relationship to study vaccination.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;38°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 39°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="57"/>
                    <measurement group_id="O5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Medically Significant Conditions (MSCs).</title>
        <description>MSCs were defined as conditions prompting emergency room visits or physician visits that were not related to common diseases or routine visits. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 = event which prevented normal activities. Related = event assessed by the investigator as causally related to the study vaccination</description>
        <time_frame>From Day 0 to Day 180</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Medically Significant Conditions (MSCs).</title>
          <description>MSCs were defined as conditions prompting emergency room visits or physician visits that were not related to common diseases or routine visits. Any = incidence of a particular symptom regardless of grade intensity or relationship with the study vaccination. Grade 3 = event which prevented normal activities. Related = event assessed by the investigator as causally related to the study vaccination</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any MSCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with grade 3 and related MSCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with related MSCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 21-day (Days 0-20) post vaccination period</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="82"/>
                    <measurement group_id="O5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Day 0 to Day 180</time_frame>
        <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK1247446A 1 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK1247446A 2 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK1247446A 3 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>GSK1247446A 4 Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Fluarix Group</title>
            <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs).</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was based on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="202"/>
                <count group_id="O5" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAE(s): during the entire study period (Day 0 - Day 180); Solicited local and general symptoms: during the 7-day (Days 0-6) follow-up period after any vaccination, Unsolicited AE(s): during the 21-day follow-up period (Days 0 to 20) after any vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK1247446A 1 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK1247446A 2 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>GSK1247446A 3 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>GSK1247446A 4 Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E5">
          <title>Fluarix Group</title>
          <description>Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="151" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="121" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="151" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="121" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Fever &gt;38°C</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="204"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

